Camlipixant is named as an intervention in 3 current clinical trials in our USA, China, UK, India, Germany, Czechia, Canada, Japan, South Korea, Taiwan and Australia registers. 2 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is GlaxoSmithKline (2). The most-studied condition is Refractory Chronic Cough.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension
NCT07650084 · ClinicalTrials.gov ↗ · Refractory Chronic Cough
|
Phase 3 | Recruiting | GlaxoSmithKline | China |
|
A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)
NCT07519395 · Irritable Bowel Syndrome
|
Phase 2 | Recruiting | GlaxoSmithKline | USA |
|
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
NCT05600777 · Cough, Refractory Chronic Cough
|
Phase 3 | Active, closed | Bellus Health Inc. - a GSK company | UK, USA, India, China, Germany, Czechia, Canada, Japan, South Korea, Taiwan, Australia |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| GlaxoSmithKline | 2 |
| Bellus Health Inc. - a GSK company | 1 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our USA, China, UK, India, Germany, Czechia, Canada, Japan, South Korea, Taiwan and Australia registers name Camlipixant (also registered as BLU-5937) as a drug or biological intervention, as of the registry sync on 28 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 3 trials are recruiting: 1 with sites in USA and 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
GlaxoSmithKline (2) and Bellus Health Inc. - a GSK company (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Camlipixant works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Camlipixant works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Camlipixant (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 28 Sep 2026.